PVH Staff, Author at Precision Value & Health

Improving Payer Engagements Around Smoking Cessation

PVH Staff2021-03-30T18:39:35+00:00News|

Three HEDIS measures had been issued by the National Committee for Quality Assurance regarding payer performance on smoking cessation among members.
Despite this, payers had a limited understanding of how smoking cessation quality measures were impacting their overall rating vs other regional health or national benchmarks. This study shows how specific smoking cessation support services were promoted to gain improvement in payer coverage for the products while adhering to PhRMA guidelines.

Commentary: 4 Ways to Create a Sustainable Pricing Model

PVH Staff2020-02-18T15:41:35+00:00Thought Leadership|

Jeremy Schafer offers his pricing model suggestions to Medical Marketing & Media.

An Incorrect Quantity Limit Leads to a Tactical Plan That Targets PBMs and Plans

PVH Staff2021-03-30T18:39:35+00:00News|

A leading pharmaceutical manufacturer had recently obtained an indication for once daily use (OaD) for erectile dysfunction to supplement its original “as needed (PRN)” indication. With quantity limits (QLs) of 4 to 8 tablets existing on its and similar PRN products, a spillover effect resulted in an accidental blanket QL placed on the drug, even when appropriately prescribed for OaD use. Discover how Precision helped get the QLs reversed.

AMCP Corporate Member Spotlight: Precision for Value President Dan Renick -AMCP News & Views

PVH Staff2020-02-18T15:41:35+00:00News|

AMCP News&Views caught up recently with Dan Renick, BS Pharmacy, RPh, President of Precision for Value, to get his thoughts on becoming a corporate member and innovations at his company.

(more…)

Biosimilars: What’s in a Name? – Pharmaceutical Commerce Magazine

PVH Staff2020-02-18T15:41:35+00:00News|

Precision for Value’s Jeremy Schafer is quoted in an article that discusses the naming of biosimilars. He concludes that the payer community will find a way to track biosimilar sourcing, usage and reimbursement regardless of naming conventions or HCPCS codes.

Precision for Medicine acquires Redwood Outcomes, a Canadian HEOR firm – Pharmaceutical Commerce Magazine

PVH Staff2020-02-18T15:41:35+00:00News|

Precision for Value, a unit of New York-based Precision for Medicine, is adding Redwood Outcomes, based in Vancouver, BC to its stable.

Commentary: Biosimilars – Why Deep Discounts May Become the Dominant Paradigm

PVH Staff2020-02-18T15:41:35+00:00Thought Leadership|

Precision for Value’s Jeremy Schafer, Michael Tapella, and Thanos Kantarelis conclude that discounts in the biosimilar market may be significantly deeper than originally expected.

Precision for Value Acquires Redwood Outcomes – NJBIZ

PVH Staff2020-02-18T15:41:35+00:00News|

Dan Renick is quoted in NJBIZ on Precision’s Redwood Outcomes HEOR acquisition.

Precision for Value Buys Health Economics Firm – Medical Marketing & Media

PVH Staff2020-02-18T15:41:36+00:00News|

Precision’s acquisition of Redwood Outcomes is noted in Medical Marketing & Media.

Press Release: Precision for Value Acquires Redwood Outcomes

PVH Staff2020-02-18T15:41:36+00:00News|

Extends Leadership and Global Reach in Health Economics and Outcomes Research

Gladstone, N.J. and Vancouver, B.C., November 4, 2015 – Precision for Value (Precision) today announced that it has acquired Redwood Outcomes, a leading international health economics and outcomes research (HEOR) company. Redwood Outcomes serves pharmaceutical and biotechnology companies and applies the science of evidence generation, synthesis, and modeling to optimize healthcare decision making.

(more…)

About PVH Staff